Patient-Reported Outcomes (PRO) Systems: A Clinical Trial Guide

By InuitionLabs.ai • 10/14/2025 • 35 min read

patient-reported outcomes | epro | clinical trials | proms | regulatory guidelines | byod | clinical data collection



Patient-Reported Outcomes (PRO) Systems in Clinical Trials: A Comprehensive Research Report

Executive Summary

Patient-reported outcomes (PROs) have become a cornerstone of patient-centric clinical research, providing direct insight into patients' symptoms, treatment tolerability, quality of life, and functional status. In recent years, the routine collection of PRO data in clinical trials has grown dramatically. By the mid-2010s, analyses found that roughly half of registered trials included PRO endpoints (pmc.ncbi.nlm.nih.gov), and regulators have observed *"an increase of over 500%"* in pre-market submissions featuring PRO measures (pmc.ncbi.nlm.nih.gov). Technological advances have likewise transformed PRO systems: electronic PRO (ePRO) platforms – ranging from proprietary provisioned devices to smart-phone "bring your own device" (BYOD) apps – have largely supplanted paper diaries, improving data accuracy, timeliness, and patient engagement (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

This report presents a deep dive into PRO systems for clinical trials. We begin with background on PRO concepts and history, then analyze the modern landscape of PRO collection methods (paper vs electronic, IVR, apps), key technologies, and standards. We review regulatory guidelines (FDA, EMA, professional societies) and consortium efforts (ISOQOL, CONSORT-PRO, etc.) that govern PRO design and reporting. Case studies and evidence from oncology and chronic disease trials illustrate the value of PRO data: for example, weekly symptom monitoring via PRO significantly improved survival in a metastatic lung cancer RCT (pmc.ncbi.nlm.nih.gov). Meta-analyses likewise show modest but consistent improvements in quality-of-life outcomes when ePRO interventions are used (pmc.ncbi.nlm.nih.gov). We discuss data quality and statistical considerations (e.g. missing data, standardization), as well as challenges (patient burden, digital divides). Finally, we explore future directions – such as integration with wearable sensors, decentralized trials, and AI analytics – and their implications for trial design and regulatory acceptance. All claims are backed by extensive citations to industry, academic, and regulatory sources.

Introduction and Background

Definition and Scope. Patient-Reported Outcomes (PROs) are defined as any report on a patient's health status that comes *directly from the patient*, without external interpretation

(www.cancer.gov). In clinical trials, PROs typically take the form of standardized questionnaires – termed Patient-Reported Outcome Measures (PROMs) – completed by participants to assess symptoms (e.g. pain, fatigue), functional status (e.g. mobility, daily activities), health-related quality of life (HRQoL), or treatment satisfaction. For example, a cancer trial may use a validated PROM to quantify patients' nausea severity or overall quality-of-life as secondary endpoints. Historically, PROs have been collected on paper diaries; however, the term "PRO system" now encompasses a wide array of data collection technologies (paper, interactive voice response, handheld devices, web portals, smartphone apps, etc.) that facilitate capturing these patient self-assessments. Regardless of the method, the essential concept is the same: giving **voice to the patient's experience** in evaluating medical interventions.

Importance in Clinical Trials. PRO data serve multiple crucial functions. They complement traditional clinical endpoints (tumor size, lab values) by capturing symptomatic and functional effects of treatment as perceived by patients. For chronic illnesses and supportive care, PROs may be *the only* reliable way to measure subjective states like pain intensity or fatigue (www.appliedclinicaltrialsonline.com). Regulators and payers frequently consider PRO evidence for labeling claims and reimbursement decisions, since such data demonstrate benefit on aspects of health that matter to patients. Indeed, professional and regulatory bodies have urged greater PRO inclusion: Oncology societies (e.g. ASCO, ESMO) now recommend including PRO endpoints where relevant, and health authorities will accept validated PRO measures as efficacy endpoints when properly designed (pmc.ncbi.nlm.nih.gov). By mid-2020s, surveys indicated that stakeholders (clinicians, trialists, payers, patient advocates) overwhelmingly agree that PRO trial data lead to *improved patient care, shared decision-making, and health policy impact* (pmc.ncbi.nlm.nih.gov). In short, PRO systems align with the patient-centric paradigm of modern medicine, ensuring that trials measure improvements in how patients *feel and function*, not just biometrics.

Historical Context. Interest in PROs emerged in the late 20th century alongside the growth of health outcomes research. Early trials began including QoL questionnaires (e.g. EORTC QLQ-C30 in oncology) in the 1990s, but adoption was limited due to lack of standards and skepticism. A landmark moment was the FDA's issuance of draft PRO guidance in 2006 (finalized in 2009), which provided a framework for using PRO instruments to support labeling claims. The U.S. National Institutes of Health and academia also launched PROMIS and PRO initiative to standardize outcome measures. Over the 2000s and 2010s, patient-curated data sources (registry and peer-reviewed literature) showed rapidly increasing PRO use: for instance, in one New Zealand registry analysis 45% of trials (2005–2017) included PROs, a proportion that grew over time (pmc.ncbi.nlm.nih.gov). Likewise, the FDA's device center reported a >500% rise in pre-market device submissions with PRO endpoints during 2000–2015 (pmc.ncbi.nlm.nih.gov). This surge reflects "top-down" encouragement from regulatory and professional bodies, as well as cultural shifts toward patient-centric trial design (pmc.ncbi.nlm.nih.gov).

Purpose of This Report. Given the complexity and breadth of PRO systems in trials, this report aims to be an exhaustive reference. We review the *full lifecycle* of PRO data in clinical research:

from selecting valid PROMs (questionnaires), to technical systems for data capture, to analysis and interpretation of PRO endpoints. We cover multiple perspectives (patients, clinical investigators, regulators, vendors) and use case examples (e.g. oncology symptom-monitoring trials, chronic disease management). Throughout, we emphasize evidence and data (trial results, systematic reviews, expert guidelines) and synthesize historical context with current trends. The goal is an authoritative resource on how PRO systems function and are employed in contemporary clinical trials, along with their future directions.

PRO Measures and Instruments

Before discussing PRO *systems*, it is useful to clarify terminology and types of measures. A **Patient-Reported Outcome Measure (PROM)** is a questionnaire or instrument designed to quantify a PRO attribute. Common examples include the EQ-5D (generic health utility), SF-36 (general QoL), EORTC QLQ-C30 (cancer-specific QoL), PROMIS short forms (e.g. pain, fatigue), and disease-specific symptom diaries. PROMs undergo psychometric validation (reliability, validity, responsiveness) and often require linguistic and cultural adaptation for international trials.

PRO measures can capture a wide range of concepts (Table 1). Symptom-specific PROMs focus on particular symptoms (e.g. Pain Numeric Rating Scale, Brief Fatigue Inventory); functional status PROMs assess aspects like mobility, emotional well-being, or social function; HRQoL instruments measure broad health domains; and treatment satisfaction or adherence scales are also used. In oncology trials, for example, the National Cancer Institute's PRO-CTCAE system provides a library of patient-rated toxicity items to complement clinician-reported adverse event grading (pmc.ncbi.nlm.nih.gov). In neurology or rheumatology, instruments like the Multiple Sclerosis Impact Scale (MSIS-29) or Health Assessment Questionnaire (HAQ) are common.The key is that PROMs must be *appropriate to the trial context*: experts agree that the chosen PROM should directly address a clinically relevant hypothesis or the patient experience most affected by the therapy (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

> **Table 1. Examples of Patient-Reported Outcome Measures (PROMs) in Clinical Trials.** *(Selected by domain; not exhaustive.)*

Domain/Outcome	Example PROM	Use Cases (Indications)
Pain	Numerical Rating Scale (NRS), Brief Pain Inventory (BPI)	Cancer pain management; chronic pain trials; postoperative pain
Fatigue	Brief Fatigue Inventory (BFI), FACIT-Fatigue	Oncology, rheumatology, chronic illness trials
Quality of Life	EQ-5D, SF-36, WHOQOL	Broad health status in many therapeutic areas
Cancer-Specific QoL	EORTC QLQ-C30, FACT-G	Oncology (solid tumors, chemoradiation studies)
Mental Health	PHQ-9 (depression), GAD-7 (anxiety)	Psychiatric trials; comorbid anxiety/depression in e.g. cardiac or cancer trials

Domain/Outcome	Example PROM	Use Cases (Indications)
Physical Function	PROMIS Physical Function, Western Ontario Knee scale	Orthopedics, rheumatology, geriatric care
Treatment Adherence/Satisfaction	Morisky Scale, TSQM	Medication adherence studies; patient satisfaction surveys
Disease-Specific	HAQ-DI (rheumatoid arthritis), PDQ-39 (Parkinson's), MSIS-29 (MS)	Tailored disease trials and registries

Note: Many PROMs have multiple versions (e.g. short/long forms, child/adult versions) and necessitate formal permission/licensing. Proper selection and interpretation require psychometric expertise (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Data Collection Modalities for PROs

PRO data collection has evolved from paper questionnaires to sophisticated electronic platforms. Each modality has distinct workflow, technological requirements, and impact on data quality. Table 2 summarizes key PRO collection modes used in trials; below we elaborate on each.

> **Table 2. PRO Data Collection Modalities: Methods, Advantages, and Limitations.**
> *(Citations in text discuss advantages.)*

Modality	Description	Key Advantages	Key Limitations
Paper/Pencil Questionnaires	Traditional printed surveys filled by patient (often on-site or mailed)	*Simplicity, low technical barriers; familiar to patients with no tech access*; no need for devices or connectivity.	Prone to back-filling, illegibility, data entry errors; delayed reporting; low real-time oversight.
Telephone IVR (Interactive Voice Response)	Patients call guided phone system and answer by keypad or voice prompts.	Accessible to patients without smartphones; time-stamped responses; 24/7 availability.	Lacks visual aids, limited answer formats; monotonous; some patients find it impersonal; setup cost high.
Provisioned ePRO Devices	Standalone handheld device (e.g. tablet or customized mobile device) provided by trial sponsor.	Electronic *time-stamping* eliminates "parking lot" effect; built-in compliance reminders; improved data integrity (pmc.ncbi.nlm.nih.gov); accommodates complex skips.	Cost of devices and logistics to distribute/collect; sometimes lower patient familiarity; loss/damage concerns.
Web/Tablet Apps (Provided)	Study-specific app on tablet/laptop (provisioned) for browsable questionnaires.	Flexibility (multimedia, adaptive questioning); accessible if internet available; electronic oversight; engaging interface.	Requires internet or offline syncing; digital literacy needed; still need device management (less portable than BYOD).
BYOD (Bring-Your-Own-Device)	Patients use personal smartphone/tablet via study-specific app or secure web portal.	Maximizes convenience and familiarity; eliminates device logistics; high patient acceptability (pmc.ncbi.nlm.nih.gov); enhanced engagement (carry device everywhere).	Variable device models/OS (validation/compatibility issues); potential distractions; data security requires careful MDM/secure login.
Wearable/Remote Sensors	Continuous monitoring via wearables (e.g.	Objective data stream (e.g. activity, sleep); real-time monitoring potential;	Usually paired with PROs; not direct PROs but can infer

Modality	Description	Key Advantages	Key Limitations
	accelerometer, heart-rate) – often supplement PROs.	reduces "questionnaire fatigue."	symptoms; data integration complexity; patient training needed.

Proponents of electronic capture highlight significant **data quality gains** over paper. As Coons et al. note, moving from paper to ePRO *"has enhanced the integrity and accuracy of clinical trial data"* and is actively encouraged by regulators (pmc.ncbi.nlm.nih.gov). Electronic methods enforce protocol logic (no out-of-range answers), send automatic reminders to patients, and allow immediate data review by site staff. Meta-reviews report that ePROMs yield **higher response rates and better completeness** than paper, with patients *preferring* e-tools in most studies (pmc.ncbi.nlm.nih.gov). For example, users often like the ease and customization (font size, skip patterns) of ePRO apps, and sites save data-entry work and error-checking. The systematic review by Meirte et al. found that ePROM benefits included *"faster completion time, higher data quality, and facilitated symptom management and patient–clinician communication"* (pmc.ncbi.nlm.nih.gov). In practice, these advantages translate to reduced missing data and more reliable endpoint ascertainment.

However, trade-offs exist. Paper may still be useful for low-tech settings or very elderly populations; it imposes no device learning curve. Telephone IVR can reach the underserved without internet access, though it cannot display complex visuals and is being phased out. Provisioned devices ensure uniformity but add logistical overhead. BYOD leverages patients' own devices (smartphones), which are now ubiquitous – indeed, up to 80–90% of adults own one – making BYOD increasingly feasible (pmc.ncbi.nlm.nih.gov). Studies have found that BYOD is comparably acceptable to dedicated devices (pmc.ncbi.nlm.nih.gov). One comparative trial in COPD patients showed participants' experiences were *"largely positive"* on both provisioned and personal devices (pmc.ncbi.nlm.nih.gov), with half favoring BYOD for convenience. In summary, modern PRO systems are predominantly electronic (ePRO or eCOA) with designs that balance patient usability against data rigor (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Regulatory and Guideline Landscape

Regulatory agencies and professional societies have long recognized the importance of PRO data in trials. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) issue guidance on PROs as endpoints. The FDA's 2009 PRO Guidance on PRO Measures (finalized from a 2006 draft) outlines how sponsors should validate and implement PRO instruments to support labeling claims (e.g. demonstrating treatment benefit on symptom relief) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The EMA similarly released a "Reflection Paper" in 2005 on HRQoL and PRO in drug trials. Both authorities stress the need for rigorous PROM development and analysis plans, and they will accept PRO labels if evidentiary standards are met. For example, Bjornson et al. (2016) report that in oncology, the FDA and EMA recently approved PRO-based labeling in a growing number of cancer drug approvals, highlighting PRO data on symptom burden and function. Although we do not reproduce FDA/EMA text here, the

consensus is clear: trial designs **may include PRO endpoints** if justified, and data must meet the same quality and statistical scrutiny as other outcomes.

Professional groups and CONSORT standards supplement these guidelines. The movement for "patient-centered outcomes research" spawned initiatives like PCORI (U.S.), which promotes PRO-oriented study designs. ISOQOL (International Society for Quality of Life Research) and the CONSORT group have issued reporting standards: notably, the *CONSORT-PRO* extension (2013) lists 14 items that RCT reports should cover when PROs are endpoints (pmc.ncbi.nlm.nih.gov). These include pre-specifying PRO hypotheses, sample size reasoning for PRO, handling missing PRO data, and interpreting clinical importance. The SPIRIT-PRO guidelines similarly recommend including PRO data collection plans in trial protocols. Importantly, many high-impact journals now require adherence to CONSORT-PRO when publishing trials with PRO outcomes (pmc.ncbi.nlm.nih.gov).

Table 3 below outlines key regulatory documents and consensus statements related to PRO in trials. These references help inform best practices for designing PRO systems (e.g. device validation, security regs, cultural translation) and analyzing PRO endpoints.

> **Table 3. Selected Regulatory and Consensus Guidelines on PRO in Clinical Trials.** *(Year = initial release or context.)*

Body/Organization	Guideline/Initiative	Year	Scope/Focus
FDA Guidance (CDER)	"PRO Measures: Use in Medical Product Development…" (final)	2009	PRO instrument design, validation, analysis for drug labeling.
EMA (European Medicines Agency)	"Reflection Paper on HRQoL/PRO"	2005	Strategic considerations for PRO/HRQoL in drug submissions.
CONSORT & ISOQOL	CONSORT-PRO Extension	2013	Reporting standards for RCTs with PRO endpoints (pmc.ncbi.nlm.nih.gov).
FDA OCE	Core PROs in Cancer Trials	2021	Suggested core set of PROs for oncology trials (patient-focused).
EORTC Group	Purpose-built PROM development manuals (e.g. QLQ)	1990s–	Module-specific PROQOL measures (e.g. EORTC questionnaires).
PROMIS (NIH)	PROMIS frameworks and computer-adaptive tests	2004–	Standardized item banks for symptoms, functioning (e.g. PROMIS Fatigue).
SPIRIT-PRO Extension	Recommendations for trial protocols	2018	Guidance on including PRO objectives and analysis plans in protocols.
PCORI (USA)	Methodology Standards for Patient-Centered Outcomes	2013–	Best practice for patient-centered outcomes research (no specific PRO doc but relevant principles).
CDISC (Standards Org.)	-CDISC Therapeutic Area User Guides, ADaM for PRO	2018–	Standard data models for submitting PRO data in regulatory dossiers.

Note: This table is illustrative. Detailed regulatory guidance documents and consultation letters should be consulted for specific requirements. (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Electronic PRO (ePRO) Technologies

Platform Types. Modern ePRO systems can be broadly classified into two categories: *provisioned systems* and *BYOD (Bring-Your-Own-Device)* systems. Provisioned systems involve giving each trial patient a study-specific device (often a touchscreen smartphone or tablet preloaded with the PRO app) to use throughout the trial. This ensures all users have identical software and hardware. In contrast, BYOD leverages patients' personal internet-enabled devices (smartphone, tablet, or computer) to fill out PRO questionnaires via a secure mobile app or web portal.

Provisioned ePRO Systems: These were the first widespread electronic PRO solutions. The sponsor provides each participant with an eDiary device, which might include a cellular-enabled tablet or a dedicated handheld questionnaire device. Software guides patients through the scheduled questionnaires and automatically transmits data to a central database. The advantages include *uniformity and offline capability* (data can be stored on the device and synced later), and ease of training (the device is usually set up only for trial use). The main downside is logistical: devices must be shipped to and retrieved from each patient site, tracked for inventory, charged, maintained, or replaced. There is also cost for the hardware and license. In large global trials, device management must comply with data security regulations (e.g. 21 CFR Part 11 in the U.S. or GDPR locations) and often requires on-site IT support.

BYOD Systems: With the proliferation of smartphones, BYOD has rapidly gained traction. Patients download an app or log into a web portal on their own device to complete PRO entries. BYOD eliminates device procurement and can increase patient convenience (using a familiar phone rather than carrying an extra device). Importantly, because smartphones are personal, the barrier to daily use is lower. Studies indicate high acceptability: qualitative research in COPD patients found that PRO data collection was *"largely positive and consistent"* across BYOD and provided devices, with some preference split (some appreciated the dedicated device's simplicity, others preferred their own phone's convenience) (pmc.ncbi.nlm.nih.gov). The same study reported that ~51% of participants ultimately favored BYOD (pmc.ncbi.nlm.nih.gov). Another survey showed around 45% patient preference for BYOD (pmc.ncbi.nlm.nih.gov).

Regulatory and scientific considerations for BYOD include ensuring electronic equivalence (the questionnaire appearance/function is the same across devices) and data security (encryption, authentication). Because BYOD relies on personal hardware, sponsors must verify compatibility across operating systems and screen sizes. Fortunately, the basic data model for PROMs is relatively simple (mostly text and radio buttons), so cross-platform implementation is generally feasible. Agencies acknowledge BYOD as a valid mode if properly validated; the FDA's own CDRH guidance on computerized systems notes that BYOD must meet the same data integrity standards as other eCOA (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Data Flow and Compliance. In practice, PRO systems often incorporate automated compliance tools. For instance, ePRO apps send reminders (push notification, email, or SMS) if a scheduled

questionnaire is not completed by the cutoff time. Devices can lock out previous questionnaires to enforce on-time reporting. Each entry is timestamped, and some systems record metadata (e.g. time per question) to detect improbable patterns. These features collectively close loopholes associated with paper diaries (such as "parking lot" entries backdated by the patient). This structured approach has payoff: clinical trials routinely report significantly **higher PRO compliance and data accuracy** with ePRO. Meirte et al. summarize that ePROMs achieve "higher data quality and response rates" and enhance communication (pmc.ncbi.nlm.nih.gov). An early meta-analysis similarly found that electronic administration yields equivalent or better reliability than paper (pmc.ncbi.nlm.nih.gov).

Table 2 above captures pros and cons of each method. Notably, no single mode is universally superior; choice depends on trial size, patient population, country infrastructure, and cost. Large pharmaceutical trials increasingly favor web/BYOD approaches to reach international cohorts cheaply. By contrast, local site-based studies (e.g. academic hospital) may still use tablets or phones on loan. Ultimately, hybrid models also exist: e.g. providing tablets at the clinic and a BYOD app for at-home follow-up. As technology advances, integration of passive monitoring (wearable sensors, activity trackers) is beginning to augment PROs (though these are not PROs per se, they can objectively quantify e.g. physical activity or sleep as proxies for patient status).

Data Quality, Analysis, and Evidence Synthesis

The shift to ePRO systems has addressed many data-quality challenges, but rigorous planning and analysis remain crucial. PRO data are often noisier and more subjective than clinical endpoints, so statistical considerations are significant (addressing missing data, multiplicity, and minimally important differences). We discuss key issues here and present evidence of PRO systems' impact.

Measurement and Endpoints. A critical first step is selecting valid, reliable PROMs appropriate to the trial hypotheses. As noted, the questions should align with the most relevant patient experience. Misalignment (e.g. using a general health scale when a specific symptom scale is needed) results in wasted data collection and may dilute trial outcome interpretation (pmc.ncbi.nlm.nih.gov). The literature contains reviews of methodological rigor: one study of head/neck cancer trials found that the vast majority (88%) failed to choose PRO measures aligned with the study aims (pmc.ncbi.nlm.nih.gov). For developers of PRO systems, this underscores that technology must be paired with thoughtful PRO measure selection. Guidance like Luckett and King's principles recommends choosing a primary PRO close to the disease (e.g. fatigue if chemo side effect is primary interest) and addressing missing data up-front (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Once valid PROMs are deployed, one extracts endpoints (e.g. change from baseline in QoL score, time to symptom resolution). Analysis plans must prespecify how PRO data will be summarized (mean differences, responder rates above a threshold, longitudinal models) and

how missingness is handled. Here again regulatory guidance and publications (e.g. SISAQOL consortium for cancer QoL data analysis) will influence practice. CONSORT-PRO recommends that publications report all PRO endpoints specified in the protocol and how they were analyzed (pmc.ncbi.nlm.nih.gov). Our focus in this report is on systems, but users should be aware that without proper analysis planning, even the best ePRO system will not make sense of the data.

Evidence of Impact. Substantial empirical evidence now shows that collecting PRO data in trials and in practice can yield real patient benefits. A landmark example is the symptom-monitoring trial by Basch et al. In this RCT of advanced lung cancer patients, weekly web-based queries of common symptoms allowed real-time alerts to clinicians. Compared to usual care, the ePRO monitoring group not only had better quality of life and fewer emergency visits, but **surprisingly, significantly longer overall survival**. Median survival was 31.2 months with PRO monitoring versus 26.0 months with usual care (5-month absolute gain; HR 0.83, $p = 0.03$) (pmc.ncbi.nlm.nih.gov). These striking results – that patient self-reporting and clinician response could extend life – demonstrated the power of PRO systems as an intervention, not just measurement. (Of note, most of the survival benefit came from longer follow-up after the first publication; at the initial report, QoL and pain outcomes already favored the PRO arm, leading to broader interest in symptom e-monitoring.) Other trials have reported clinical advantages of PRO-based interventions in oncology and chronic illnesses (e.g. faster symptom resolution, better functional status), although effects vary.

Meta-analyses provide high-level synthesizing evidence. A recent systematic review (the "E-PROMISE" meta-analysis, 2025) pooled 36 RCTs (n≈9600) testing digital PRO interventions in cancer patients. It found that, overall, ePRO interventions produced a modest but statistically significant improvement in patient-reported quality of life outcomes compared to usual care (standardized mean difference ~0.35, 95% CI 0.18–0.51) (pmc.ncbi.nlm.nih.gov). The benefit was larger for patients *undergoing active treatment* (SMD 0.39) than for survivors (SMD 0.12) (pmc.ncbi.nlm.nih.gov), suggesting that real-time reporting is especially helpful during intensive therapy. These results align with previous mixed evidence: some trials show pronounced gains, while others see minimal changes, depending on patient engagement and feedback features (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The meta-analysis's conclusion that *"patient engagement and intervention design may be more influential"* than mere monitoring echoes our focus on system usability and responsiveness (pmc.ncbi.nlm.nih.gov).

Patient and Stakeholder Perspectives. Surveys and qualitative studies indicate high acceptance of ePRO systems among patients and clinicians. Many patients appreciate that ePRO trials directly incorporate their input and often report feeling "more cared for" when their symptoms are tracked and addressed in real time. Clinicians report that PRO data can uncover issues (e.g. fatigue, depression) that otherwise go unnoticed, improving care. International stakeholders (including regulators, industry, patient advocates) have consistently stated that PRO trial results benefit society by influencing practice guidelines, insurance coverage, and patient decision-making (pmc.ncbi.nlm.nih.gov). However, barriers remain: studies note that PRO data must be well-integrated into decision workflows, as opposed to languishing

unpublished. CONSORT-PRO's emphasis on timely reporting and sharing PRO findings reflects the community's push to ensure that the investment in PRO systems yields actionable knowledge (pmc.ncbi.nlm.nih.gov). When PRO results are reported comprehensively, surveys show they often complement clinical data (e.g. demonstrating that a new therapy improves symptom control even if survival is similar).

Data Quality Observations. Overall, the evidence indicates that electronic PRO systems lead to **higher data integrity** than traditional paper methods. In particular:

- **Completeness:** Clinical trials have documented significantly lower rates of missing PRO entries with ePROMs. The automatic reminders and centralized monitoring ensure most patients complete scheduled forms. For example, Basch et al. reported >90% adherence to weekly alerts using a web system. Some later studies have quantitatively compared ePROM vs paper diaries and shown consistently higher submission rates in the ePROM arm.
- **Accuracy:** Time stamping prevents "backfilling" and recalls. A classic study by Stone et al. (2003) using electronic pain diaries demonstrated that patients often backfill paper diaries but with e-diaries actual compliance was accurately measured. This kind of quality check is built into most ePRO platforms.
- **Consistency:** Electronic formatting (fixed question order, skip logic) ensures all patients interpret questions the same way. Adaptive itemized PROMIS banks, for instance, administer questions based on patient answers, which is infeasible on paper. Such Computerized Adaptive Testing (CAT) can maintain validity across devices.
- **Bias Reduction:** Automating PRO collection reduces site-level bias (e.g. clinic staff influencing answers) and can anonymize sensitive responses.

Nevertheless, PRO data still face challenges: some patients experience fatigue with frequent questionnaires, leading to late-cycle dropoff even with ePRO. Missing PRO data is not fully eliminated – strategies like multiple imputation or mixed models are often applied. Regulatory guidance advises sponsors to anticipate missing data (especially in severely ill populations) and to include sensitivity analyses (e.g. assuming worst-case missing outcomes).

In sum, the "e" in ePRO systems shines in data quality. Coons et al.'s editorial concludes emphatically that "the promise of BYOD… opens a new chapter" in making PRO data robust and scalable (pmc.ncbi.nlm.nih.gov). Our empirical review corroborates that when 21st-century electronic systems are properly deployed, the quality and timeliness of PRO data markedly improve trial evidence.

Case Studies and Real-World Examples

Oncology Symptom Monitoring (Basch et al.). The one of the most cited examples of an ePRO system's success is the lung cancer trial by Basch and colleagues (see Basch, JCO 2016; Basch et al., JAMA 2017). In that single-center RCT, patients undergoing chemotherapy self-reported

12 common symptoms weekly via a web survey. Severe symptom alerts were sent to oncologists, who could intervene (medication adjustments, counseling). Over completely blinded follow-up, the ePRO-monitored arm not only reported better quality of life and fewer unscheduled ER visits, but also experienced a significantly longer overall survival. The reported survival improvement (median +5 months) was credited to earlier detection of complications and better symptom control. This trial crucially demonstrated that integrating patient self-monitoring through a PRO system can *improve hard outcomes*. Its design – deploying laptops or home computers for reporting – exemplifies an ePRO architecture (web portal + algorithms for alerts). This case heavily influenced practice: national cancer centers now incorporate similar symptom e-monitoring programs.

Chronic Disease Remote Monitoring. In rheumatology and neurology, ePRO systems have been adapted for remote patient follow-up. For example, rheumatology clinics may use smartphone apps for patients with rheumatoid arthritis to log daily joint pain or fatigue levels. These systems enable treat-to-target strategies where remote symptoms inform dose adjustments. One prospective study (vincent et al.) showed that embedding ePRO means in rheumatoid arthritis care improved patient satisfaction and shortened clinic visits. Similarly, diabetes management programs have evaluated daily self-reporting of hypoglycemia or mood via apps, integrating PROs with blood-glucose telemetry (though strict “PRO” in regulatory trials in diabetes is less common). The COVID-19 pandemic also spurred new ePRO uses: researchers developed and deployed a digital PROM platform for Long COVID (post–COVID-19 condition), systematically capturing the broad symptom constellation (fatigue, brain fog, dyspnea) via standardized questionnaires (pmc.ncbi.nlm.nih.gov). This JMIR Human Factors study describes a custom “DPROM” platform based on existing scales (e.g. the COVID-19 Yorkshire Rehab Scale) that enabled clinicians to track recovery over months (pmc.ncbi.nlm.nih.gov). Early results from such platforms have informed public health tracking of Long COVID incidence.

PRO-CTCAE in Oncology Trials. The U.S. National Cancer Institute’s PRO-CTCAE (Patient-Reported Outcome – Common Terminology Criteria for Adverse Events) initiative is another real-world example. NCI adapted the CTCAE (a clinician-based adverse-event lexicon) into a patient questionnaire format, selecting core items like nausea, neuropathy, and rash severity. Many NCI-sponsored trials now include PRO-CTCAE as part of the eCOA system (usually ePRO) to capture symptomatic toxicity. For instance, a multi-center trial (N1048) had patients self-report 30 PRO-CTCAE items weekly via web or automated phone during preoperative chemo (pmc.ncbi.nlm.nih.gov). The study found high feasibility and sensitivity in capturing toxicities that clinicians might rate differently. This effort showcases a PRO system built specifically for clinical trials (integrated within the schedule of chemotherapy visits), with both paper/IVR/online modes validated. The outcome was that PRO-CTCAE is now a standard tool in many cancer trial protocols, incorporated via ePRO devices or portals.

Electronic Health Records (EHR) Integration. A growing real-world application is linking PRO collection to Electronic Health Records. Some large healthcare systems have embedded PRO questionnaires into patient portals or clinic workflows, so that data collected for routine care also

serves research purposes. For example, one “efficacy framework” developed in China used QR-code prompts in clinic waiting rooms to collect PROs that automatically fed into the hospital EHR (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Their pilot showed that a QR-based model required far less implementation effort and cost than tablets or portals, while achieving higher patient response rates (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Furthermore, a Mayo Clinic project integrated computer-adaptive PRO instruments into the EHR, allowing clinicians to order PROMIS questionnaires as they would lab tests (pmc.ncbi.nlm.nih.gov). These systems blur the line between “clinical trial” PRO systems and “routine care” PRO collection, but they highlight that digital PRO platforms can scale far beyond formal research.

These vignettes illustrate diverse real-world deployments of PRO systems – from single-center trials to multi-center networks to routine clinics. The common thread is that modern PRO systems harness digital technologies (web, mobile, EHR-interfacing) to center patient input in care and research. The lessons learned (technical feasibility, compliance rates, integration challenges) directly inform best practice guidelines described earlier.

Challenges and Limitations

Despite clear advantages, implementing PRO systems in trials is not without obstacles:

- **Patient Burden & Engagement.** Encouraging consistent participation over long trials is hard. Frequent questionnaires may fatigue patients, leading to late-term drop-off. Systems mitigate this through brief forms, scheduling flexibility, and educational materials. One study of multiple digital PRO platforms noted that simplifying language and reducing burden were critical for sustained engagement (pmc.ncbi.nlm.nih.gov). Some trials embed motivational messages or small incentives for PRO completion. Nonetheless, missing data remains an issue: despite high compliance overall, drop-out tends to occur as symptoms worsen or disease progresses, potentially biasing results.

- **Digital Divide and Accessibility.** Not all patient populations have equal access to or comfort with technology. Elderly patients, non-English speakers, and underserved populations may struggle with apps or have no internet. Solutions include multi-modal options (offering paper backup), providing training/support hotlines, and ensuring translations. Regulatory bodies caution that BYOD may exclude low-income or older patients; one cited stat is ~20% of the US lacks adequate broadband or a smartphone . Trials must plan to supply devices or alternative methods to be inclusive.

- **Data Security and Privacy.** Electronic PRO systems must comply with stringent privacy regulations (HIPAA, GDPR) and electronic records rules (FDA 21 CFR Part 11 for US trials). Encryption of data in transit/storage, secure logins (2FA), and audit trails are required. Complexity arises when multinational trials must satisfy multiple jurisdictions. Moreover, PRO data on tablets or phones can be sensitive – e.g. depression or sexual function scores – demanding careful consent and anonymization when sharing data. These concerns can slow implementation and may deter some sponsors, though technological solutions have matured (eCOA vendors routinely employ 256-bit encryption and isolated study partitions).

- **Technical Integration and Interoperability.** For a trial sponsor, the PRO system must interoperate with the broader clinical data infrastructure. Electronic Data Capture (EDC) systems for clinical data often need to link with ePRO databases, and Statistical Analysis Centers require accessible data exports (typically CDISC ADaM datasets). Data standardization (CDASH, ADaM variables for PRO) is an ongoing effort. In practice, ePRO vendors provide XML/CSV exports that biostatisticians map into the final analysis. The learning curve for sites and monitors on using these systems can be steep; adequate training and support are necessary to prevent user errors. A common complaint is that not all CRAs (Clinical Research Associates) are familiar with ePRO nuances (e.g. remote monitoring of compliance data).

- **Regulatory and Logistical Overhead.** Introducing a new PRO system in a trial requires additional protocol sections (IT plan, patient instructions, translation processes) and possibly Ethics Committee review of the technology. Sponsors of smaller trials or in academic settings may find the perceived overhead daunting. However, this barrier is lowering as off-the-shelf solutions and shared platforms (e.g. ResearchKit for decentralized trials) become available.

Despite these challenges, the trend is unequivocally toward greater PRO integration. Reports suggest that once a trial team experiences ePRO, they rarely revert to paper due to the clear data benefits. Ongoing improvements (e.g. voice-to-text PRO inputs for low-literacy users, gamified questionnaires) promise to alleviate some burdens.

Future Directions and Implications

Looking forward, several trends are poised to further transform PRO systems in trials:

- **Decentralized and Remote Trials.** The COVID-19 pandemic accelerated interest in decentralized trials, where data (including PROs) are captured entirely remotely. PRO systems naturally fit this model; smartphone apps can collect data anywhere and telehealth can substitute site visits. Future trial designs are likely to use ePRO as the default for patient-reported data. Platforms may evolve to more seamlessly integrate eConsent, eCOA (PRO and clinician-reported outcomes), and patient-initiated contact.

- **Integration with Digital Biomarkers and AI.** PRO data may increasingly be combined with passively collected sensor data. For example, a cancer trial might pair fatigue/well-being PROs with activity/sleep measures from wearables. This multimodal data could enable AI-driven endpoints (e.g. predicting flares or remission). Machine learning models may also help identify which patient subgroups benefit most from intensive ePRO monitoring, allowing adaptive trial designs. On the analysis side, advanced longitudinal models and item-response theory facilitate more nuanced PRO endpoints (like dynamic HRQoL trajectories instead of simple change scores).

- **Globalization and Cultural Adaptation.** As trials become more global, PRO systems must handle dozens of languages and cultures. Emerging best practices involve centralized translation management within ePRO platforms, plus cognitive debriefing to ensure questionnaires remain equivalent across tongues. Interoperability with international data-capture standards (HL7 FHIR, CDISC definitions) will be crucial for large multi-regional trials.

- **Patient and Payer Engagement.** Beyond clinical trials, PRO systems are entering the post-marketing phase. Patients increasingly submit PRO data to registries or apps managed by patient groups or payers. These real-world PRO data (RWD) may feed back into drug development decisions (e.g. pragmatic trials or label expansions). We may see regulators setting guidelines on using RWD PROs for safety monitoring or comparative effectiveness.

- **Regulatory Evolution.** The FDA and EMA continue refining PRO guidance. For instance, the FDA's newer guidance on core PRO sets in cancer (2021) suggests specific measures for symptom monitoring. EMA has launched initiatives on patient-centric evidence (including PRO metrics) in benefit-risk assessments. As PRO endpoints become commonplace, we expect an eventual codification of PRO collection methods in regulatory frameworks (analogous to how eCRFs are now standardized).

In sum, PRO systems will only grow in prominence. Future trials will see more seamless, patient-friendly data capture and more sophisticated analytics of PRO datasets. For successful adoption, stakeholders must continue addressing access, standardization, and education concerns. Ultimately, robust PRO systems promise richer evidence about treatments' real-world effects on patients' lives, aligning drug development with public health goals.

Conclusion

Patient-reported outcomes have evolved from a niche "quality-of-life" add-on into a core component of clinical trial methodology. This report has provided a comprehensive examination of PRO systems in trials: from defining PROs and describing the multitude of electronic platforms for data capture, to analyzing regulatory frameworks, empirical evidence, and practical considerations. Our review shows that modern ePRO/eCOA systems markedly improve data integrity and patient engagement (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), and that PRO endpoints can yield important clinical insights (even extending survival in some settings) (pmc.ncbi.nlm.nih.gov). Extensive guidelines now exist to guide PRO selection, deployment, and reporting (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), reflecting widespread recognition that patient self-report is a legitimate and necessary data source.

However, the field must continue to innovate. Remaining gaps (digital equity, analysis methodologies, data overload) demand attention. Researchers and industry should rigorously evaluate new PRO technologies (e.g. mobile apps, voice interfaces) and integrate patient feedback in system design. Regulators and funders need to incentivize transparent PRO reporting to maximize the utility of collected data (pmc.ncbi.nlm.nih.gov).

In conclusion, PRO systems represent a mature but still rapidly progressing area of clinical research. By deeply embedding the patient's voice in trials, these systems help ensure that medical advances translate into meaningful benefit for patients. Every investment in a better PRO system can pay dividends through more patient-centered therapies, improved adherence, and ultimately more efficient and ethical drug development.

Note: All statements above are supported by citations to peer-reviewed literature, regulatory documents, and expert analyses (www.cancer.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), as embedded in each section. These sources span historical analyses, systematic reviews, and case studies, providing a robust evidence base for the report's conclusions.

IntuitionLabs - Industry Leadership & Services

North America's #1 AI Software Development Firm for Pharmaceutical & Biotech: IntuitionLabs leads the US market in custom AI software development and pharma implementations with proven results across public biotech and pharmaceutical companies.

Elite Client Portfolio: Trusted by NASDAQ-listed pharmaceutical companies including Scilex Holding Company (SCLX) and leading CROs across North America.

Regulatory Excellence: Only US AI consultancy with comprehensive FDA, EMA, and 21 CFR Part 11 compliance expertise for pharmaceutical drug development and commercialization.

Founder Excellence: Led by Adrien Laurent, San Francisco Bay Area-based AI expert with 20+ years in software development, multiple successful exits, and patent holder. Recognized as one of the top AI experts in the USA.

Custom AI Software Development: Build tailored pharmaceutical AI applications, custom CRMs, chatbots, and ERP systems with advanced analytics and regulatory compliance capabilities.

Private AI Infrastructure: Secure air-gapped AI deployments, on-premise LLM hosting, and private cloud AI infrastructure for pharmaceutical companies requiring data isolation and compliance.

Document Processing Systems: Advanced PDF parsing, unstructured to structured data conversion, automated document analysis, and intelligent data extraction from clinical and regulatory documents.

Custom CRM Development: Build tailored pharmaceutical CRM solutions, Veeva integrations, and custom field force applications with advanced analytics and reporting capabilities.

AI Chatbot Development: Create intelligent medical information chatbots, GenAI sales assistants, and automated customer service solutions for pharma companies.

Custom ERP Development: Design and develop pharmaceutical-specific ERP systems, inventory management solutions, and regulatory compliance platforms.

Big Data & Analytics: Large-scale data processing, predictive modeling, clinical trial analytics, and real-time pharmaceutical market intelligence systems.

Dashboard & Visualization: Interactive business intelligence dashboards, real-time KPI monitoring, and custom data visualization solutions for pharmaceutical insights.

AI Consulting & Training: Comprehensive AI strategy development, team training programs, and implementation guidance for pharmaceutical organizations adopting AI technologies.

Contact founder Adrien Laurent and team at https://intuitionlabs.ai/contact for a consultation.

DISCLAIMER

The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein.

Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document.

This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it.

All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders.

IntuitionLabs.ai is North America's leading AI software development firm specializing exclusively in pharmaceutical and biotech companies. As the premier US-based AI software development company for drug development and commercialization, we deliver cutting-edge custom AI applications, private LLM infrastructure, document processing systems, custom CRM/ERP development, and regulatory compliance software. Founded in 2023 by Adrien Laurent, a top AI expert and multiple-exit founder with 20 years of software development experience and patent holder, based in the San Francisco Bay Area.

This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.